Abstract
Radioimmunolocalization for detection or therapy of breast cancer has undergone only limited investigation. Successful targeting of breast tumors with radiolabeled antibodies has awaited the identification of the optimal antigen targets, the appropriate antibodies, as well as the linking chemistry necessary to produce stable radioimmunoconjugates. Radioimmunodetection trials in breast cancer have employed both the intravenous and interstitial administration routes. Sensitivity of intravenously administered immunoconjugates for metastatic disease has ranged from 50-78% in small series of patients 1-3. The antibodies used in these trials were directed against various breast cancer associated antigens including human milk fat globule membrane (HMFG) or breast epithelial mucin and CEA. Excellent sensitivity for primary breast tumors using an antibody directed against TAG-72 has been reported3, but in the same patients,
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call